| Id |
Subject |
Object |
Predicate |
Lexical cue |
| TextSentencer_T1 |
0-45 |
Sentence |
denotes |
Role of chromosome 9 in human bladder cancer. |
| TextSentencer_T2 |
46-281 |
Sentence |
denotes |
The tumors of 20 patients with multifocal primary transitional cell carcinoma of the bladder or lymph node metastases were examined for molecular genetic defects which we have previously found to be present in > 50% of invasive tumors. |
| TextSentencer_T3 |
282-501 |
Sentence |
denotes |
These included loss of heterozygosity (LOH) of chromosome 9, which occurs in superficial as well as invasive bladder tumors, and LOH of chromosome 17p and p53 mutations, which are commonly found only in invasive tumors. |
| TextSentencer_T4 |
502-769 |
Sentence |
denotes |
Analysis of multiple or recurrent primary tumors in 7 patients for these markers was generally consistent with recently published data that the tumors are monoclonal in origin and that p53 mutations occur as a late event in the generation of invasive bladder cancers. |
| TextSentencer_T5 |
770-1049 |
Sentence |
denotes |
Comparison of the primary tumors and metastases to regional lymph nodes in 14 patients demonstrated a complete concordance between the molecular genetic defects present, showing that LOH of chromosomes 9 and 17p and p53 mutations occurred in the primary tumors before metastasis. |
| TextSentencer_T6 |
1050-1273 |
Sentence |
denotes |
Because of the importance of chromosome 9 in bladder cancer, we mapped the location of a putative tumor suppressor gene by restriction fragment length polymorphism analysis of 123 cases obtained in this and earlier studies. |
| TextSentencer_T7 |
1274-1345 |
Sentence |
denotes |
Most of the tumors showed LOH for more than one marker on chromosome 9. |
| TextSentencer_T8 |
1346-1490 |
Sentence |
denotes |
Results of mapping of 4 tumors with partial deletion of chromosome 9 suggests that the tumor suppressor gene is located between 9p12 and 9q34.1. |
| T1 |
0-45 |
Sentence |
denotes |
Role of chromosome 9 in human bladder cancer. |
| T2 |
46-281 |
Sentence |
denotes |
The tumors of 20 patients with multifocal primary transitional cell carcinoma of the bladder or lymph node metastases were examined for molecular genetic defects which we have previously found to be present in > 50% of invasive tumors. |
| T3 |
282-501 |
Sentence |
denotes |
These included loss of heterozygosity (LOH) of chromosome 9, which occurs in superficial as well as invasive bladder tumors, and LOH of chromosome 17p and p53 mutations, which are commonly found only in invasive tumors. |
| T4 |
502-769 |
Sentence |
denotes |
Analysis of multiple or recurrent primary tumors in 7 patients for these markers was generally consistent with recently published data that the tumors are monoclonal in origin and that p53 mutations occur as a late event in the generation of invasive bladder cancers. |
| T5 |
770-1049 |
Sentence |
denotes |
Comparison of the primary tumors and metastases to regional lymph nodes in 14 patients demonstrated a complete concordance between the molecular genetic defects present, showing that LOH of chromosomes 9 and 17p and p53 mutations occurred in the primary tumors before metastasis. |
| T6 |
1050-1273 |
Sentence |
denotes |
Because of the importance of chromosome 9 in bladder cancer, we mapped the location of a putative tumor suppressor gene by restriction fragment length polymorphism analysis of 123 cases obtained in this and earlier studies. |
| T7 |
1274-1345 |
Sentence |
denotes |
Most of the tumors showed LOH for more than one marker on chromosome 9. |
| T8 |
1346-1490 |
Sentence |
denotes |
Results of mapping of 4 tumors with partial deletion of chromosome 9 suggests that the tumor suppressor gene is located between 9p12 and 9q34.1. |
